"MON-459 ONO-5788, a Novel Oral Small Molecule Somatostatin Receptor Type-2 (SST2) Agonist, Attenuates GH Hypersecretion in Human GH-Secreting, Pituitary Adenoma-Derived Cells" by Cuiqi Zhou

Article

MON-459 ONO-5788, a Novel Oral Small Molecule Somatostatin Receptor Type-2 (SST2) Agonist, Attenuates GH Hypersecretion in Human GH-Secreting, Pituitary Adenoma-Derived Cells

Journal of the Endocrine Society (2019)

Cuiqi Zhou, Cedars-Sinai Medical Center
Vivien Bonert, Cedars-Sinai Medical Center
Adam Mamelak, Cedars-Sinai Medical Center
Daniel Kelly, Brain Tumor Center & Pituitary Disorders Program, Pacific Neuroscience Institute, John Wayne Cancer Institute, Santa Monica, CA, United States
Garni Barkhoudarian, Pacific Neuroscience Institute, John Wayne Cancer Institute, Santa Monica, CA, United States
Dave Hoon
Tatsuya Komagata, Ono Pharmaceuticals Co. Ltd, Osaka, , Japan
Koji Shinozaki, Ono Pharmaceuticals Co. Ltd, Osaka, , Japan
Shlomo Melmed, Cedars-Sinai Medical Center

Link

Disciplines

Internal Medicine and
Endocrinology

Publication Date

April 15, 2019

DOI

10.1210/js.2019-mon-459

Citation Information

Cuiqi Zhou, Vivien Bonert, Adam Mamelak, Daniel Kelly, et al.. "MON-459 ONO-5788, a Novel Oral Small Molecule Somatostatin Receptor Type-2 (SST2) Agonist, Attenuates GH Hypersecretion in Human GH-Secreting, Pituitary Adenoma-Derived Cells" Journal of the Endocrine Society Vol. 3 (2019)
Available at: http://works.bepress.com/dave-hoon/314/